This presentation covers the latest insights and updates on how to effectively conduct due diligence for acquisitions in the life sciences sector, considering the dynamic legal, regulatory, and compliance environment.
This presentation examines the evolving regulatory landscape of clinical research compliance, emphasizing how multiple federal and state agencies—beyond the FDA—are shaping enforcement priorities in the clinical trial space.